Good
Mostly Aligned
Patient Risk:
Low
Summary
The AI response correctly identifies several supported reconstitution instructions (gently swirl—do not shake; solution clarity; do not use if cloudy or discolored; clouding considerations after refrigeration). It also marks multiple claims as not present or partially supported by the 2.4 label excerpt. Overall alignment is good with notable omissions and interpretation beyond the provided label content.
Category Scores
Accurate Statements
Gently swirl—do not shake—to dissolve the powder.
2.4 Reconstitution: 'Aim the stream of diluent against the side of the vial to prevent foaming and gently swirl the vial with a rotary motion until the contents are completely dissolved and the solution is clear. Do not shake the vial since shaking or vigorous mixing will cause the solution to be cloudy.'
The solution should be clear.
2.4 Reconstitution: 'until the contents are completely dissolved and the solution is clear.'
If cloudy or discolored, do not use.
2.4 Reconstitution: 'Inspect visually for particulate matter and discoloration. If the resulting solution is cloudy or contains particulate matter do not use.'
Occasionally, after refrigeration, some cloudiness may occur. Allow the product to warm to room temperature. If cloudiness persists or particulate matter is noted do not use.
2.4 Reconstitution: 'Occasionally, after refrigeration, some cloudiness may occur. Allow the product to warm to room temperature. If cloudiness persists or particulate matter is noted do not use.'
Unsupported Statements
Store reconstituted Zomactent (somatropin) solution in a refrigerator at 36°F to 46°F (2°C to 8°C).
Label excerpt provided does not specify an exact temperature range for storage.
Do not freeze.
No explicit 'do not freeze' instruction appears in the provided 2.4 text.
Protect from light by keeping the vial in the original carton.
No guidance on light protection in the 2.4 excerpt.
Use within 21 days from the date of reconstitution.
No 21-day window is specified in the 2.4 reconstitution section.
Reconstituted Zomactent remains stable for up to 21 days when refrigerated.
Stability data for 21 days is not provided in the 2.4 section.
Discard any unused portion after this period, even if liquid remains.
Label states to discard the unused portion, but does not specify a 21-day period.
If frozen, discard the solution—do not use it.
No explicit instruction about freezing is provided in the excerpt.
If exposed to temperatures above 77°F (25°C), discard unless it was only briefly out of refrigeration.
No such temperature/discard guidance appears in the provided text.
Avoid leaving it at room temperature for more than a few hours total.
No explicit guidance on room-temperature duration is provided in the excerpt.
Keep it refrigerated during travel using a cooler with ice packs.
No travel refrigeration guidance is provided in the excerpt.
Airlines allow it in carry-on with documentation.
No airline carry-on guidance is provided in the excerpt.
Plan to use or discard within the 21-day window.
No 21-day usage/discard window is stated in the excerpt.
Use only the provided diluent (bacteriostatic water for injection).
Label specifies diluents but does not explicitly say 'provided' diluent.
The solution should be clear.
Duplicate of an accurate statement; already categorized as accurate.
Contradictions
Important Omissions
No explicit indication of a 21-day reconstitution stability window or storage temperature range beyond general refrigeration.
Importance:
High
No explicit contraindications content in the 2.4 excerpt; contraindications and boxed warnings are not shown in this excerpt.
Importance:
High
No pregnancy risk category information in this excerpt; pediatric safety/dosing details not provided here.
Importance:
High
No dosing amounts or titration guidance beyond reconstitution details; no administration/administration-related safety details beyond swirl/shake guidance.
Importance:
High
Safety Assessment
Potential Patient Risk:
Low
Assessment limited to reconstitution guidance; identified accurate handling statements and general omissions. No specific patient-level risk is inferred beyond standard cautions already present in the label excerpt.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Substantial omissions present (e.g., no temperature guidance, no 21-day window, no light-protection guidance, no contraindications/boxed warnings) and some claims asserted as 'provided' diluent or usage window are not supported by the 2.4 excerpt.
Suggested Improvement
Annotate claims with exact label-supported language; avoid inferring time windows or handling guidance not present in the provided excerpt; include explicit references to any additional label sections if evaluating beyond 2.4.